ATE349225T1 - Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv - Google Patents

Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv

Info

Publication number
ATE349225T1
ATE349225T1 AT98959859T AT98959859T ATE349225T1 AT E349225 T1 ATE349225 T1 AT E349225T1 AT 98959859 T AT98959859 T AT 98959859T AT 98959859 T AT98959859 T AT 98959859T AT E349225 T1 ATE349225 T1 AT E349225T1
Authority
AT
Austria
Prior art keywords
hcv
tubulin
annexin
proteins
apo
Prior art date
Application number
AT98959859T
Other languages
English (en)
Inventor
Geert Maertens
Erik Depla
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE349225T1 publication Critical patent/ATE349225T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
AT98959859T 1997-11-06 1998-11-06 Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv ATE349225T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97870178 1997-11-06

Publications (1)

Publication Number Publication Date
ATE349225T1 true ATE349225T1 (de) 2007-01-15

Family

ID=8231062

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98959859T ATE349225T1 (de) 1997-11-06 1998-11-06 Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv

Country Status (8)

Country Link
US (1) US6670114B1 (de)
EP (1) EP1028742B1 (de)
JP (1) JP2001522809A (de)
AT (1) ATE349225T1 (de)
AU (1) AU756303B2 (de)
CA (1) CA2305715A1 (de)
DE (1) DE69836758T2 (de)
WO (1) WO1999024054A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
EP1127170A4 (de) 1998-11-05 2005-04-27 Univ Leland Stanford Junior Menschliche monoklonale antikörper gegen menschlichen pan-hepatitis c virus
US6815160B1 (en) * 1999-07-28 2004-11-09 Chiron Corporation Hepatitis C viral antigen immunoassay detection systems
US20020160936A1 (en) * 1999-09-29 2002-10-31 Howard J. Worman Hcv e2 protein binding agents for treatment of hepatitis c virus infection
GB9927320D0 (en) 1999-11-18 2000-01-12 Chiron Spa Exosome separation
AU2002229581A1 (en) * 2000-12-01 2002-06-11 Innogenetics N.V. Proteins binding hcv and their medical, diagnostic and purification use
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
AU2002252035A1 (en) 2001-02-21 2002-09-12 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
ITMI20040891A1 (it) * 2004-05-04 2004-08-04 Ibsa Inst Biochimique Sa Nuovo metodo per la partizione ed inattivazione di contaminanti virali e prionici
GB0413001D0 (en) 2004-06-10 2004-07-14 Johnson & Johnson Medical Ltd Diagnostic and prognostic
US20060057591A1 (en) * 2004-09-15 2006-03-16 Canadian Blood Services Method for preventing viral infection
JP7432529B2 (ja) 2018-05-30 2024-02-16 プロメガ コーポレイション 広域スペクトルキナーゼ結合剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3734015A1 (de) * 1987-10-08 1989-04-20 Behringwerke Ag Diagnostisches mittel und verfahren zur bestimmung von apolipoprotein b
US5206086A (en) * 1987-10-13 1993-04-27 University Of Rochester Particle-stabilized epitopes for standardization and control of immunoassays
US5187068A (en) * 1989-06-09 1993-02-16 Nicolae Luca Method for determination of lipid moiety and apolipoprotein expressed epitope immunoreactivity on intact lipoprotein
DE4206574C1 (en) * 1992-03-02 1993-08-26 Reiner Prof. Dr. 3400 Goettingen De Thomssen Fractionation method of parts of hepatitis C virus - by concn. of complexes of virus parts and lipoprotein(s) having low densities useful in hepatitis C virus detection and distinction of variants
WO1994001554A1 (en) * 1992-07-08 1994-01-20 N.V. Innogenetics S.A. Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
DE69526636T3 (de) * 1994-07-29 2006-11-23 Innogenetics N.V. Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung

Also Published As

Publication number Publication date
DE69836758D1 (de) 2007-02-08
JP2001522809A (ja) 2001-11-20
CA2305715A1 (en) 1999-05-20
DE69836758T2 (de) 2007-10-11
EP1028742A1 (de) 2000-08-23
AU1561099A (en) 1999-05-31
WO1999024054A1 (en) 1999-05-20
US6670114B1 (en) 2003-12-30
EP1028742B1 (de) 2006-12-27
AU756303B2 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
ATE349225T1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
DE69533855D1 (de) UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
EA199801044A1 (ru) Модуляторы регенерации тканей
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE68919229D1 (de) Hybride prokoagulierende proteine.
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
DE59109221D1 (de) HCV-spezifische Peptide, Mittel dazu und ihre Verwendung
DK0737207T3 (da) Inhibitorer for humant plasmin afledt af Kunitz-domæner
DE69942708D1 (de) Virus enthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE69631544D1 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
ATE373016T1 (de) Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers
DE69327755D1 (de) Zusammensetzung zum Unterdrücken von Infektion und Wachstum des menschlichen Immunschwäche-Virus unter Verwendung eines eisenbindenden Proteins
DE60217326D1 (de) Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DE69631443D1 (de) Reagens zur untersuchung von viren-agglutination und kit zur untersuchung auf viren
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DE50002164D1 (de) Peptide zur inhibierung von hpv e6-proteinen
TR199801769T2 (xx) D���k reg�lasyona diren�li C3 d�n��t�r�c�ler.
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
DE60124523D1 (de) Zusammensetzung einer Parvovirus VP1-Proteinvariante und eines arvovirus NS1-Proteins zur Induktion von Zytolyse
DE69629121D1 (de) Verwendung eines 24 kD Proteins zur Behandlung und Diagnose einer HCV Infektion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties